PharmaIN introduces a new paradigm to effective drug delivery in vivo. Our technology, at the "nanomedicine" or molecular level, delivers a drug to where it can act. There is a vast pool of drug candidates - particularly peptides - that are in need of enabling and more appropriate targeting technologies like those provided by PharmaIN.

The human body is a complex organism. This complexity is possible because interacting proteins, peptides, hormones, and other molecules have specific roles. This specificity can be illustrated by the "lock and key" analogy. The biochemist, on the otherhand, understands and explains molecule specificity through the "dissociation constant", one measurement of affinity between interacting molecules. We take advantage of the differential affinities that exist between interacting molecules in our design of optimal carrier molecules, our drug delivery vehicles, thus creating or enabling potentially superior therapies to treat human disease.

Our innovative and unique approach to drug delivery focuses on three key interactions, quantified by a dissociation constant (or "K_d") or its reciprocal, the association constant ("K_a"):

A) "Receptor and Drug" - this interaction should have high affinity (the highest of the three for a good therapy, a therapy with minimal side effects).

B) "Carrier and Drug" - this interaction should have strong affinity, but weaker than that of a drug and target receptor (so the drug remains a payload until the stronger affinity of the target receptor is present). We can control this interaction to a great extent.

C) "Unintended target and Drug" - this interaction should be the weakest of all three. The affinity between a chosen drug and an unwanted target(s) should play a very minor role in releasing drug payload from the carrier, i.e. the carrier holds drug payload tightly until the higher affinity strength interaction with a target receptor is encountered.

Our proprietary, and patented, drug delivery platform emphasizes the importance of exploiting the difference between affinities, so that: A > B > C (affinity strengths for each interaction). Simplistically, we create carrier molecules to hold a drug payload, shepherd that payload to its intended target, and then release the drug. Biochemically, our drug delivery carrier molecules are designed to release a drug "payload" under conditions favoring the kinetics/thermodynamics surrounding an effective interaction between a drug and its intended target. Our drug delivery strategy and technology helps lower unintended interactions, interactions or reactions that are often responsible for undesirable side effects of a drug.